Advances in chemotherapy for patients with extremity soft tissue sarcoma. Review uri icon

Overview

abstract

  • Doxorubicin-based chemotherapy does not appear to offer a survival benefit to patients who have high-risk primary extremity soft tissue sarcomas, whereas ifosfamide-based chemotherapy does. This benefit is likely histology- and size-specific. Until a less toxic targeted systemic therapy is developed, treatment with ifosfamide should be strongly considered in patients who have high-risk primary extremity soft tissue sarcomas.

publication date

  • January 1, 2006

Research

keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Neoadjuvant Therapy
  • Neoplasm Invasiveness
  • Sarcoma

Identity

Scopus Document Identifier

  • 28344447733

Digital Object Identifier (DOI)

  • 10.1016/j.ocl.2005.07.001

PubMed ID

  • 16311108

Additional Document Info

volume

  • 37

issue

  • 1